Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: A prospective multicenter trial

Lauri M. Burroughs, Eneida R. Nemecek, Troy R. Torgerson, Barry E. Storer, Julie An Talano, Jennifer Domm, Roger H. Giller, Akiko Shimamura, Colleen Delaney, Suzanne Skoda-Smith, Monica S. Thakar, K. Scott Baker, David J. Rawlings, Janet A. Englund, Mary E.D. Flowers, H. Joachim Deeg, Rainer Storb, Ann E. Woolfrey

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Hematopoietic cell transplantation is an effective treatment for patients with nonmalignant diseases and for many is the only known cure. Conventional myeloablative regimens have been associated with unacceptably high early transplant-related mortality (TRM), particularly in patients with comorbid conditions. This prospective multicenter trial was designed to determine the safety and engraftment efficacy of treosulfan-based conditioning in patients with nonmalignant diseases. Thirty-one patients received HLA-matched related (n=4) or unrelated (n=27) grafts after conditioning with treosulfan (total dose, 42g/m2), fludarabine (total dose, 150mg/m2), ± thymoglobulin (6mg/kg; n=22). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. All patients engrafted. Day-100 TRM was 0%. With a median follow-up of 2years, the 2-year survival was 90%. Three patients died of GVHD, recurrent hemophagocytic lymphohistiocytosis, and a surgical complication, respectively. The cumulative incidences of grades II to IV and III to IV acute GVHD at day 100 and chronic GVHD at 2years were 62%, 10%, and 21%, respectively. Patients who received thymoglobulin had a significantly lower incidence of grades III to IV acute GVHD (0% versus 33%; P=.005). These results indicate that the combination of treosulfan, fludarabine, and thymoglobulin is effective at establishing donor engraftment with low toxicity and improved survival in patients with nonmalignant diseases and support the need for future disease-specific clinical trials.

Original languageEnglish (US)
Pages (from-to)1996-2003
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number12
DOIs
StatePublished - Dec 1 2014

    Fingerprint

Keywords

  • Allo-transplantation
  • Clinical results in inherited disorders
  • Conditioning regimen
  • Nonmalignant diseases
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Burroughs, L. M., Nemecek, E. R., Torgerson, T. R., Storer, B. E., Talano, J. A., Domm, J., Giller, R. H., Shimamura, A., Delaney, C., Skoda-Smith, S., Thakar, M. S., Baker, K. S., Rawlings, D. J., Englund, J. A., Flowers, M. E. D., Deeg, H. J., Storb, R., & Woolfrey, A. E. (2014). Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: A prospective multicenter trial. Biology of Blood and Marrow Transplantation, 20(12), 1996-2003. https://doi.org/10.1016/j.bbmt.2014.08.020